Eye Health Academy

11/10/2021

How can we ensure that our most vulnerable patients with DME have the best chance for a good outcome? Learn more now: https://bit.ly/3H9DjmP

New anti-angiogenic treatments are emerging that extend beyond current VEGF targets to reduce treatment burden and improve vision outcomes in DME. Explore how these new treatments work and examine the latest data around their use with our experts, Dr Christina Weng and Dr. Arshad Khanani.

11/03/2021

& : How Can You Achieve Durable VEGF Suppression? Learn more about the latest evidence: https://bit.ly/3q0HQle

09/29/2021

Can we improve outcomes in diabetic macular edema by going beyond VEGF inhibition? Join us to learn more: https://bit.ly/3F0wbrV

09/18/2021

RVO puts patients at high risk for loss. Do you know the best strategies to individualize treatment & optimize vision in these patients? https://bit.ly/3EpKgPg

09/09/2021

Despite advances in treatment for nAMD, visual outcomes remain suboptimal. How can we improve outcomes in our nAMD patients?

The incidence of neovascular age-related macular degeneration (nAMD) is rising as a large segment of the US population ages. Despite recent advances in treatment, frequent injections and monitoring visits create a burden on patients that often leads to nonadherence, undertreatment, and suboptimal vi...

09/01/2021

[EARN ]: See the latest surgical approaches for durable VEGF suppression & learn about new technologies that are coming to the office & the OR. https://bit.ly/3kI4qeh

08/25/2021

How do physicians distinguish key pathological features to identify early neovascular age-related macular degeneration & retinal vein occlusion before macular edema leads to permanent vision loss? https://bit.ly/2WpSIN3

08/18/2021

How does someone decide that Locum Tenens is right for them? Join us to find out: https://bit.ly/37WY9pb

08/11/2021

Discover the latest evidence for new & emerging agents in nAMD & DME that can provide durable anti-VEGF suppression & reduce treatment burden. https://bit.ly/3yFRR9d

07/29/2021

When time is vision, how can you address your patients’ fears & tailor therapy to achieve long-term success in the management of wet AMD?

Age-related macular degeneration (AMD) is the most common cause of blindness in adults over the age of 50 years. Anti-VEGF therapy has markedly improved vision outcomes in patients with neovascular AMD, but what else can we do to maximize long-term vision in these patients? Drs. Do, Haller, and Sing...

07/21/2021

Since 2012, at least 27 astronauts have been diagnosed with spaceflight-associated neuro-ocular syndrome, but where does this health threat land now? https://bit.ly/3BtGDGo